| Literature DB >> 32591536 |
Xiaoyong Du1, Ye Xiao1, Jia-Ming Huang1, Yao Zhang1, Ya-Nan Duan1, Heng Wang1, Chuan Shi1, Gen-Qiang Chen2,3, Xumu Zhang4.
Abstract
AsymmetriEntities:
Year: 2020 PMID: 32591536 PMCID: PMC7319995 DOI: 10.1038/s41467-020-17057-z
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Fig. 1Biologically active compounds and drugs derived from chiral carboxylic acid.
Ibuprofen and Naproxen (nonsteroidal anti-inflammatory drugs); (R)-Tiagabine (γ-aminobutyric acid reuptake inhibitor); Artemisinin (antimalarial drug); Rupintrivir (rhinovirus protease inhibitor); (S)-Equol (soy isoflavonoid metabolite); Sacubitril (antihypertensive drug used in combination with Valsartan).
Fig. 2Transition metal-catalyzed asymmetric hydrogenation of α,β-unsaturated carboxylic acids.
a Previous work: noble metal-based catalysts. b This work: cobalt-catalyzed asymmetric hydrogenation of α,β-unsaturated carboxylic acids.
Fig. 3The performance of chiral diphosphine ligands in Co-catalyzed asymmetric hydrogenation of 1a.
The yields were determined by 1H NMR and the enantioselectivities were determined by HPLC analysis in all cases.
Optimization for cobalt-catalyzed asymmetric hydrogenation of (E)-2,3-diphenylacrylic acid.
| Entry | Additive | Solvent | Conv. (%)a | ee (%)b | |
|---|---|---|---|---|---|
| 1 | 5 | — | MeOH | 70 | 94 |
| 2 | 5 | — | >98 | 93 | |
| 3c | 5 | — | TFE | >98 | 84 |
| 4 | 5 | — | DME | 7 | 43 |
| 5 | 5 | — | Toluene | 15 | 86 |
| 6 | 5 | — | THF | NR | — |
| 7 | 5 | — | 1,4-Dioxane | NR | — |
| 8 | 1 | — | 61 | 93 | |
| 9 | 1 | Cs2CO3 | 7 | 88 | |
| 10 | 1 | KO | 55 | 93 | |
| 11 | 1 | Mn | >98 | 96 | |
| 12 | 1 | Zn | >98 | 97 | |
| 13d | 1 | Zn | >98 | 97 | |
| 14e | 0.1 | Zn | >98 | 97 | |
| 15e | 0.05 | Zn | 93 | 97 | |
TFE trifluoroethanol, DME dimethoxyethane, THF tetrahydrofuran.
Conditions: 1a (0.1 mmol) in solvent (0.6 mL) under 60 atm H2 pressure at 50 °C for 24 h.
aDetermined by 1H NMR.
bDetermined by HPLC analysis.
cUsing TFE (0.6 mL) and THF (0.6 mL) as solvent.
dUnder 40 atm H2, room temperature.
e2 mmol scale, under 80 atm H2, 7 d.
Fig. 4Cobalt-catalyzed asymmetric hydrogenation of various α,β-unsaturated carboxylic acids.
aConditions: 1 (0.1 mmol), Co(acac)2 (1 mol%), (S,S)-Ph-BPE (1 mol%) and Zn (10 mol%) in iPrOH (0.6 mL) under 40 atm H2 pressure at room temperature for 24 h. Yield of isolated products, unless noted otherwise. The ee values were determined by HPLC analysis. bUnder 60 atm H2 pressure, 50 °C. cUnder 80 atm H2 pressure, 50 °C. dWith 5 mol% of Cat. eWith 5 mol% of CoCl2 and (S,S)-Ph-BPE in MeOH (0.4 mL), 72 h. f3 (0.1 mmol), CoCl2 (5 mol%), (S,S)-Ph-BPE (5 mol%), and Zn (50 mol%) in HFIP (0.4 mL) under 60 atm H2 pressure at 50 °C for 48 h. gIn 0.6 mL solvent (MeOH/HFIP = 2/1), 72 h. hIn 0.4 mL MeOH.
Fig. 5Practical synthetic applications of cobalt-catalyzed asymmetric hydrogenation.
a Synthesis of (S)-Equol intermediate via cobalt-catalyzed hydrogenation. b Synthesis of Rupinnavir intermediate. c Synthesis of Sacubitril intermediate. d Asymmetric synthesis of Naproxen. e Asymmetric synthesis of Ibuprofen. f Gram-scale asymmetric hydrogenation of artemisinic acid 5.
Fig. 6Control experiments and mechanistic investigations.
a Hydrogenation of ester 1b′ under standard conditions. b Hydrogenation of ester 1b′ in the presence of catalytic amount of CH3COOH. c Reaction of ester 1b′ in the presence of catalytic amount of 1b. d Deuterium-labeling experiment. e Hydrogenation of 1b in isopropanol-d8 with CH3COOD as additive.
Fig. 7Proposed catalytic cycle.
a Generation of catalytic species E in the absence of Zn. b Generation of catalytic species E in the presence of Zn. c Proposed catalytic cycle.